HUP9900848A2 - Alacsony Ostwald-koefficiensű, fluortartalmú éterekkel stabilizált gáz emulziók - Google Patents

Alacsony Ostwald-koefficiensű, fluortartalmú éterekkel stabilizált gáz emulziók

Info

Publication number
HUP9900848A2
HUP9900848A2 HU9900848A HUP9900848A HUP9900848A2 HU P9900848 A2 HUP9900848 A2 HU P9900848A2 HU 9900848 A HU9900848 A HU 9900848A HU P9900848 A HUP9900848 A HU P9900848A HU P9900848 A2 HUP9900848 A2 HU P9900848A2
Authority
HU
Hungary
Prior art keywords
ocf2
gas emulsions
fluorine
ether
gas
Prior art date
Application number
HU9900848A
Other languages
English (en)
Inventor
Alexey Kabalnov
Ernest George Schutt
Jeffry Greg Weers
Original Assignee
Alliance Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp. filed Critical Alliance Pharmaceutical Corp.
Publication of HUP9900848A2 publication Critical patent/HUP9900848A2/hu
Publication of HUP9900848A3 publication Critical patent/HUP9900848A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

A találmány tárgyát űltrahangős és mágneses rezőnancia leképezéséhezkőntraszt növelésére szőlgáló, és egyéb területeken alkalmazhatóalacsőny Ostwald-kőefficiensű, flűőr-mőnő- és flűőr-pőliéter-vegyületekkel stabilizált gázeműlziók képezik. A találmány tővábbá azilyen gázeműlziók előállítására, valamint az ilyen eműlziókelőállításáhőz prekűrzőr kőmpőzíciókra is vőnatkőzik. A találmányszerinti gázeműlziók őlyan mikrőbűbőrék-készítményeket tartalmaznak,ahől a mikrőbűbőrékők egy flűőr-étert, előnyösen perflűőr-diglimet[CF3(OCF2CF2)2OCF3], perflűőr-mőnőglimet (CF3OCF2CF2OCF3), perflűőr-dietil-étert (C2F5OC2F5), perflűőr-etil-metil-étert (CF3OC2F5),perflűőr-dimetil-étert (CF3OCF3), valamint CF3OCF2OCF3 képletű étertés flűőr-pőliétereket[CF3(OCF2)2OCF3, CF3(OCF2)3OCF3 ésCF3(OCF2)4OCF3] tartalmaznak. ŕ
HU9900848A 1995-06-07 1996-06-05 Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients HUP9900848A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/479,621 US5804162A (en) 1995-06-07 1995-06-07 Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients

Publications (2)

Publication Number Publication Date
HUP9900848A2 true HUP9900848A2 (hu) 1999-07-28
HUP9900848A3 HUP9900848A3 (en) 1999-11-29

Family

ID=23904745

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900848A HUP9900848A3 (en) 1995-06-07 1996-06-05 Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients

Country Status (18)

Country Link
US (2) US5804162A (hu)
EP (2) EP0833669B1 (hu)
JP (1) JP4067116B2 (hu)
KR (1) KR100401429B1 (hu)
CN (1) CN1087954C (hu)
AT (2) ATE216894T1 (hu)
AU (1) AU712946B2 (hu)
CA (1) CA2222186A1 (hu)
CZ (1) CZ391397A3 (hu)
DE (2) DE69621015T2 (hu)
DK (1) DK0833669T3 (hu)
ES (2) ES2176462T3 (hu)
HU (1) HUP9900848A3 (hu)
IL (1) IL122217A (hu)
NO (1) NO975317L (hu)
PL (1) PL185883B1 (hu)
PT (1) PT833669E (hu)
WO (1) WO1996040281A2 (hu)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
CA2164813C (en) * 1993-07-30 2009-11-24 Ernest G. Schutt Stabilized microbubble compositions for ultrasound
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
CA2252617A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
AU727764B2 (en) * 1996-08-05 2000-12-21 Schering Aktiengesellschaft Process for the production of contrast media for magnetic resonance tomography
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
DK1323434T3 (da) 1996-09-11 2007-11-12 Bristol Myers Squibb Medical I Fremgangsmåde til diagnostisk billeddannelse af nyreregioner under anvendelse af et kontrastmiddel og en vasodilator
HU224218B1 (hu) * 1996-10-21 2005-06-28 Amersham Health As Továbbfejlesztett kontrasztanyagok
AU5161298A (en) * 1996-11-25 1998-06-22 Imarx Pharmaceutical Corp. Perfluorinated-ether compositions as diagnostic contrast agents
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002506625A (ja) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド サイトカインレセプター共通γ鎖様
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6270460B1 (en) * 1999-06-24 2001-08-07 Acuson Corporation Apparatus and method to limit the life span of a diagnostic medical ultrasound probe
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6849194B2 (en) 2000-11-17 2005-02-01 Pcbu Services, Inc. Methods for preparing ethers, ether compositions, fluoroether fire extinguishing systems, mixtures and methods
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
US7300743B2 (en) * 2003-03-06 2007-11-27 E. I. Du Pont De Nemours And Company Radiation durable organic compounds with high transparency in the vacuum ultraviolet, and method for preparing
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
US20050074406A1 (en) * 2003-10-03 2005-04-07 Scimed Life Systems, Inc. Ultrasound coating for enhancing visualization of medical device in ultrasound images
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
HUE040063T2 (hu) 2005-07-19 2019-02-28 Stemgen S P A Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
NZ568204A (en) 2005-10-13 2012-01-12 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
AU2009241762B2 (en) * 2008-05-02 2015-07-16 Celsense Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US20100160576A1 (en) * 2008-11-21 2010-06-24 University Of Tennessee Research Foundation Perfluorinated poly(oxymethylene) compounds
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
JP2013180956A (ja) * 2012-02-29 2013-09-12 Sunstar Engineering Inc 殺菌剤組成物
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
CN104353088A (zh) * 2014-09-30 2015-02-18 东南大学 一种脂质气泡的制备方法
US10052394B2 (en) 2014-11-21 2018-08-21 General Electric Company Microbubble tether for diagnostic and therapeutic applications
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3176206A1 (de) * 2015-12-01 2017-06-07 Evonik Degussa GmbH Verfahren zur herstellung feinzelliger schaumstoffe unter verwendung eines zellalterungshemmers
AU2017260532B2 (en) 2016-05-04 2024-08-22 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11225689B2 (en) 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
EP3654993A4 (en) 2017-07-17 2021-08-25 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH WITH HEMORRHAGIC RECTO-COLITIS
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3937969A1 (en) 2019-03-14 2022-01-19 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
TW202428311A (zh) 2022-07-14 2024-07-16 美商博得學院股份有限公司 藉由與運鐵蛋白受體的相互作用實現ｃｎｓ範圍之基因傳遞的ａａｖ衣殼
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
CA1170569A (en) * 1980-11-17 1984-07-10 Julia S. Rasor Microbubble precursors and methods for their production and use
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
DE3313947A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3324754A1 (de) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen Ultraschallkontrastmittel sowie dessen herstellung
GB8504916D0 (en) * 1985-02-26 1985-03-27 Isc Chemicals Ltd Emulsions of perfluorocarbons in aqueous media
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4613326A (en) * 1985-07-12 1986-09-23 Becton, Dickinson And Company Two-component medication syringe assembly
DE3529195A1 (de) * 1985-08-14 1987-02-26 Max Planck Gesellschaft Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
DE3785054T2 (de) * 1986-01-24 1993-07-08 Childrens Hosp Medical Center Stabile emulsionen von stark fluorierten, organischen verbindungen.
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
DE3741201A1 (de) * 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
DE3741199A1 (de) * 1987-12-02 1989-08-17 Schering Ag Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
WO1989006978A1 (en) * 1988-02-05 1989-08-10 Schering Aktiengesellschaft Berlin Und Bergkamen Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
IN172208B (hu) * 1990-04-02 1993-05-01 Sint Sa
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5556610A (en) * 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
GB9009423D0 (en) * 1990-04-26 1990-06-20 Williams Alun R Assessment of vascular perfusion by the display of harmonic echoes from ultrasonically excited gas bubbles
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5315997A (en) * 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
DK0504340T3 (da) * 1990-10-05 1995-08-21 Bracco Int Bv Fremgangsmåde til fremstilling af stabile suspensioner af hule gasfyldte mikrokugler egnet til ultralyd-ekkografi
DE4100470A1 (de) * 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2063529A1 (en) * 1991-03-22 1992-09-23 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
EP0586524B2 (en) * 1991-06-03 2000-11-02 Nycomed Imaging As Improvements in or relating to contrast agents
US5607661A (en) * 1991-07-05 1997-03-04 Nycomed Imaging As Aggregates of x-ray microparticles for ultrasound imaging
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
WO1993003671A1 (en) * 1991-08-13 1993-03-04 Molecular Biosystem, Inc. Method of mri imaging using diamagnetic contrast agents
DK0605477T4 (da) * 1991-09-17 2007-10-01 Ge Healthcare As Gasformige ultralydskontrastmidler
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
WO1993006869A1 (en) * 1991-10-04 1993-04-15 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5196183A (en) * 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
DE4219723A1 (de) * 1992-06-13 1993-12-16 Schering Ag Mikropartikel, Verfahren zu deren Herstellung, sowie die Verwendung dieser in der Diagnostik
WO1994001140A1 (de) * 1992-07-03 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Echokontrastmittelzubereitung
DK0660724T3 (da) * 1992-09-16 1998-11-02 Nycomed Imaging As Forberinger vedrørende kontrastmidler
US5314644A (en) * 1992-10-19 1994-05-24 Virginia Polytechnic Institute And State University Microbubble generator
CA2148372A1 (en) * 1992-11-02 1994-05-11 Margaret A. Wheatley Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
PL176116B1 (pl) * 1993-01-25 1999-04-30 Sonus Pharma Inc Środek kontrastowy do ultrasonografii i sposób wytwarzania środka kontrastowego do ultrasonografii
EP0693924B2 (en) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
GB9305349D0 (en) * 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
US5333613A (en) * 1993-03-23 1994-08-02 Delineate Microparticles as ultrasonic contrast media
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US5798091A (en) * 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
HU225495B1 (en) * 1993-12-15 2007-01-29 Bracco Research Sa Gas mixtures useful as ultrasound contrast media
DE4406474A1 (de) * 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5562893A (en) * 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
GB9808599D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or realting to contrast agents
GB9808582D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or relating to contrast agents

Also Published As

Publication number Publication date
EP0833669A2 (en) 1998-04-08
MX9709564A (es) 1998-10-31
NO975317L (no) 1998-01-09
DK0833669T3 (da) 2002-08-12
CN1192159A (zh) 1998-09-02
JP4067116B2 (ja) 2008-03-26
EP0833669B1 (en) 2002-05-02
DE69621015T2 (de) 2002-12-19
CA2222186A1 (en) 1996-12-19
EP1174153B1 (en) 2006-08-23
HUP9900848A3 (en) 1999-11-29
US6193952B1 (en) 2001-02-27
DE69636486D1 (de) 2006-10-05
DE69636486T2 (de) 2007-05-03
WO1996040281B1 (en) 2001-04-05
AU6048796A (en) 1996-12-30
ATE216894T1 (de) 2002-05-15
ATE337018T1 (de) 2006-09-15
JPH11506782A (ja) 1999-06-15
US5804162A (en) 1998-09-08
ES2176462T3 (es) 2002-12-01
CZ391397A3 (cs) 1998-05-13
ES2269262T3 (es) 2007-04-01
DE69621015D1 (de) 2002-06-06
CN1087954C (zh) 2002-07-24
PL185883B1 (pl) 2003-08-29
EP1174153A2 (en) 2002-01-23
KR100401429B1 (ko) 2004-02-18
KR19990022594A (ko) 1999-03-25
WO1996040281A2 (en) 1996-12-19
IL122217A0 (en) 1998-04-05
WO1996040281A3 (en) 1997-03-13
NO975317D0 (no) 1997-11-19
AU712946B2 (en) 1999-11-18
IL122217A (en) 2002-03-10
PT833669E (pt) 2002-09-30
PL323868A1 (en) 1998-04-27
EP1174153A3 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
HUP9900848A2 (hu) Alacsony Ostwald-koefficiensű, fluortartalmú éterekkel stabilizált gáz emulziók
ATE281183T1 (de) Stabilisierte mikrogasblaeschen-zusammensetzungen für echografie
PT78602A (de) Verfahren zur herstellung von 1-triazolyl-ethylether-derivaten
ATE409719T1 (de) Verfahren zur herstellung fester treibmittelpräparationen
AU2003232207A1 (en) Cless thansbgreater than10less than/sbgreater than-alkanolalkoxylates and the use thereof
JPS6426522A (en) Single phase composition
HUP0302099A2 (hu) Az azithromicin monohidrátja, eljárás az előállítására és a monohidrátot tartalmazó gyógyszerkészítmény
KR850004469A (ko) 살균제의 제조방법
ATE390397T1 (de) Fluorierte biphenylverbindungen zur verwendung in flüssigkristallmischungen
JPH06279081A (ja) セメントモルタル・コンクリート硬化体の製造方法
DK557487D0 (da) Polyfluorerede forbindelser og fremgangsmaade til fremstilling deraf
EP0255717A3 (en) Ganglioside related compounds and method of producing the same
IL81677A (en) Preparation of optically active phenoxyalkanoltriazole compounds and an alkene oxide intermediate therefor
Carlson et al. Ultrastructure of isolated basement membranes in the acellular human renal cortex
SU907046A1 (ru) Полировальна суспензи
KR920011921A (ko) γ- FeOOH 분말의 제조방법
DE59304845D1 (de) Fluorsubstituierte Epoxycyclo- und Epoxybicyclo(2.2.1)Heptan-Derivate sowie Verfahren zur Herstellung
Keyworth Science at the Margins—The Impact of Multidisciplinary Research on the Vitality of Research
ATE147716T1 (de) Fluorsubstituierte vicinale glykole, ein verfahren zu ihrer herstellung sowie ihre verwendung
AU7620681A (en) Cephalosporins
EP0359117A3 (de) Cycloalkylvinylether, deren Herstellung und Verwendung
RU97116528A (ru) Способ получения 2-метил-5-[ди(трифторметил)оксиметил]фурана
BG40479A3 (en) Method for preparing phenylethyr compounds